文献速递肿瘤 PET/CT

FDG-PET/CT上宫颈肿瘤及盆腔淋巴结代谢活性用于局部晚期宫颈癌腹主动脉旁手术分期分层

Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-08

研究纳入125例局部晚期宫颈癌、术前FDG-PET/CT腹主动脉旁淋巴结(PALN)摄取阴性且行腹主动脉旁淋巴结清扫的患者,评估宫颈肿瘤及盆腔淋巴结(PLN)代谢参数预测PALN转移的价值。FDG-PET/CT在PLN有摄取与无摄取患者中的假阴性率分别为27.7%(13/47)和5.1%(4/78);预测PALN受累最佳参数为PLN与肿瘤SUVmax比值。作者认为PLN摄取阴性者PALN转移风险很低,PALN清扫似乎不合理;PLN有摄取者手术分期使超过25%病例治疗改变,应行手术分期。

要点

  • FDG-PET/CT PLN无摄取者PALN假阴性率5.1%(4/78),PLN有摄取者27.7%(13/47)。
  • 预测PALN受累最佳代谢参数为PLN与肿瘤SUVmax比值,AUC 0.85(0.72-0.98)。
  • PLN有摄取者手术分期使超过25%病例治疗改变,作者认为应行手术分期。

核心结论

  • FDG-PET/CT PLN阴性患者PALN转移风险很低,因此腹主动脉旁淋巴结清扫似乎不合理。
  • 术前FDG-PET/CT PLN有摄取者,手术分期使超过25%病例治疗改变,因此应行手术分期。
  • 有超过一个阳性PLN且PLN代谢活性高者,腹主动脉旁扩展和复发风险高。
  • 需进一步前瞻性评估以考虑不经先前PALN清扫的强化治疗模式。

研究设计与样本

  • 研究纳入局部晚期宫颈癌、术前FDG-PET/CT PALN摄取阴性且行腹主动脉旁淋巴结清扫的患者。
  • 两名擅长妇科肿瘤的资深核医学医师审阅所有PET/CT检查,提取肿瘤及PLN的SUVmax、MTV和TLG。
  • 采用ROC曲线和逻辑回归分析识别PALN受累的预后参数。
  • 共纳入125例连续局部晚期宫颈癌患者。

主要发现

  • FDG-PET/CT假阴性率在PLN有摄取患者为27.7%(13/47),在PLN无摄取患者为5.1%(4/78)。
  • 宫颈肿瘤大小、SUVmax、MTV、TLG的AUC分别为0.75(0.62-0.87)、0.59(0.44-0.76)、0.75(0.60-0.90)、0.71(0.56-0.86)。
  • PLN大小、SUVmax、SUVmean、PLN SUVmax/肿瘤SUVmax比值、MTV、TLG的AUC分别为0.57(0.37-0.78)、0.82(0.68-0.95)、0.77(0.61-0.94)、0.85(0.72-0.98)、0.69(0.51-0.87)、0.74(0.57-0.91)。
  • 预测PALN受累在敏感性和特异性之间最佳权衡的代谢参数为PLN与肿瘤SUVmax比值。

关键数值与推荐

  • FDG-PET/CT PLN有摄取患者PALN假阴性率为27.7%(13/47)。
  • FDG-PET/CT PLN无摄取患者PALN假阴性率为5.1%(4/78)。
  • PLN与肿瘤SUVmax比值预测PALN受累的AUC为0.85(0.72-0.98)。

临床怎么用

  • 作者认为FDG-PET/CT PLN阴性患者PALN转移风险很低,腹主动脉旁淋巴结清扫似乎不合理。
  • 作者认为术前FDG-PET/CT PLN有摄取者应行手术分期,因手术分期使超过25%病例治疗改变。
  • 作者指出有超过一个阳性PLN且PLN代谢活性高者腹主动脉旁扩展和复发风险高。
  • 作者提出需进一步前瞻性评估以考虑不经先前PALN清扫的强化治疗模式。

局限性

  • 需进一步前瞻性评估以考虑不经先前PALN清扫的强化治疗模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of our study was to comprehensively evaluate the most valuable metabolic parameters of cervical tumours and pelvic lymph nodes (PLN) by FDG-PET/CT to predict para-aortic lymph node (PALN) metastasis and stratify patients for surgical staging. METHODS: The study included patients with locally advanced cervical cancer, negative PALN uptake on preoperative FDG-PET/CT, and para-aortic lymphadenectomy. Two senior nuclear medicine physicians expert in gynaecologic oncology reviewed all PET/CT exams, and extracted tumour SUVmax, MTV, and TLG, as well as PLN. Prognostic parameters of PALN involvement were identified using ROC curves and logistic regression analysis. RESULTS: One hundred and twenty-five consecutive locally advanced cervical cancer patients were included. The FDG-PET/CT false-negative rate was, respectively, 27.7% (13/47) and 5.1% (4/78) in patients with and without FDG-PET/CT PLN uptake. The AUC of cervical tumour size, SUVmax, MTV, and TLG was, respectively, 0.75 (0.62-0.87), 0.59 (0.44-0.76), 0.75 (0.60-0.90), and 0.71 (0.56-0.86). The AUC of PLN size, SUVmax, SUVmean, PLN SUVmax/Tumour SUVmax ratio, MTV, and TLG was, respectively, 0.57 (0.37-0.78), 0.82 (0.68-0.95), 0.77 (0.61-0.94), 0.85 (0.72-0.98), 0.69 (0.51-0.87), and 0.74 (0.57-0.91). The metabolic parameter showing the best trade-off between sensitivity and specificity to predict PALN involvement was the ratio between PLN and tumour SUVmax. CONCLUSION: The risk of PALN metastasis in FDG-PET/CT negative PLN patients is very low, so para-aortic lymphadenectomy does not seem justified. In patients with preoperative PLN uptake on FDG-PET/CT, surgical staging led to treatment modification in more than 25% of cases and should therefore be performed. Patients with more than one positive PLN and high PLN metabolic activity are at high risk of para-aortic extension and recurrence. Further prospective evaluation is required to consider intensified treatment modalities without prior PALN dissection.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Martinez A, Voglimacci M, Lusque A, et al. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 31915897. doi:10.1007/s00259-019-04659-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。